Monopar Therapeutics (MNPR) Selling, General & Administrative (2017 - 2026)
Powered by 
Analysis
Monopar Therapeutics (MNPR) Selling, General & Administrative (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 582.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 662.10 Mn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | -417.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 216.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 110.21 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 593.21 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 161.89 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 247.47 Mn |
| 10 | Monopar Therapeutics | 1.01 Bn | 952.35 Mn | - | 1.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.88 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Sep 30, 2024 | 590,624.00 |
| Jun 30, 2024 | 657,806.00 |
| Mar 31, 2024 | 757,281.00 |
| Dec 31, 2023 | 876,397.00 |
| Sep 30, 2023 | 749,474.00 |
| Jun 30, 2023 | 733,496.00 |
| Mar 31, 2023 | 871,675.00 |
| Dec 31, 2022 | 806,030.00 |
| Sep 30, 2022 | 675,115.00 |
| Jun 30, 2022 | 684,877.00 |
| Mar 31, 2022 | 779,254.00 |
| Dec 31, 2021 | 698,441.00 |
| Sep 30, 2021 | 631,698.00 |
| Jun 30, 2021 | 615,965.00 |
| Mar 31, 2021 | 687,936.00 |
| Dec 31, 2020 | 628,377.00 |